Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Nurix Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
31.1
17.8
29.8
38.6
77
54.5
84
Research and development
45
66.5
116
184
189
222
317
General and administrative
8.33
16.3
31.2
38
42.9
45.9
52.7
Operating expenses
53.4
82.8
148
222
232
268
370
Operating income
-22.2
-65
-118
-184
-155
-213
-286
Pre-tax income
-21.5
-63.8
-117
-180
-144
-193
-264
Income tax
0.24
-20.5
0.13
0
0
0.27
0.76
Net income
-21.7
-43.2
-117
-180
-144
-194
-264
EBITDA
-19.9
-62.8
-115
-179
-148
-204
-277
EPS, basic
-6.59
-2.76
-2.73
-3.71
-2.65
-2.88
-3.05
EPS, diluted
-6.59
-2.76
-2.73
-3.71
-2.65
-2.88
-3.05
Shares, basic (weighted)
3.29
15.7
42.9
48.6
54.3
67.1
86.7
Shares, diluted (weighted)
3.29
15.7
42.9
48.6
54.3
67.1
86.7
Dividend per share
0.00
0.00
0.00
0.00
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
34.8
119
80.5
64.5
54.6
110
247
Short-term investments
2.9
162
215
245
Receivables
6
0
0
Other current assets
1.63
5.94
9.19
9.31
7.6
9.8
13.9
Total current assets
39.4
298
311
318
296
619
607
Property, plant and equipment
3.87
6.67
11.3
17.2
16.8
17.8
22.5
Lease right-of-use assets
14
12.3
31.1
28.1
50.5
Long-term investments
0.51
90.9
137
63.9
Other non-current assets
0.15
0.18
2.83
4.02
3.82
3.16
7.34
Total assets
44
396
477
417
356
669
688
Accounts payable
1.6
3.41
6.65
5.06
6.4
11.5
11.2
Accrued liabilities
3.75
5.73
8.85
13.2
15.3
16.6
21.5
Deferred revenue
9.61
32.8
41.2
37.6
48.1
38.4
17.6
Total current liabilities
16.1
44.5
66.3
70.7
87
95.9
86.5
Lease liabilities
9.19
6.43
23.1
20.3
52.9
Other non-current liabilities
1.74
0.85
Total liabilities
53.6
106
134
113
155
142
149
Paid-in capital
2.74
394
564
709
746
1,266
1,542
Retained earnings
-60.5
-104
-221
-401
-545
-739
-1,003
Other comprehensive income
-0
0.09
-0.61
-4.32
-0.66
0.15
0.11
Shareholders' equity
-57.7
290
342
304
200
527
539
Total equity
-57.7
290
342
304
200
527
539
Total liabilities and equity
44
396
477
417
356
669
688
Shares outstanding
3.6
38.9
44.7
47.2
48.7
75.9
102
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-21.7
-43.2
-117
-180
-144
-194
-264
Depreciation and amortization
2.35
2.18
2.79
5.35
7.53
9.32
8.74
Stock-based compensation
0.51
4.3
15.8
28.1
33.7
33.9
38
Change in receivables
-6
6
0
0
Change in payables
0.3
1.23
1.59
0.09
1.61
5.21
-0.63
Cash from operations
0.6
-0.08
-84.4
-160
-81.4
-173
-249
Capital expenditures
-1.65
-4.55
-5.66
-12.2
-8.4
-9.27
-14
Purchases of investments
-9.35
-275
-348
-239
-246
-708
-456
Sales and maturities of investments
19.5
25.4
239
279
323
460
618
Cash from investing
8.5
-254
-108
27.2
68.3
-258
148
Stock issued
0.14
218
150
19.4
0
290
0
Cash from financing
0.13
339
154
117
3.22
486
239
Net change in cash
9.23
84.5
-38.7
-15.4
-9.85
55.4
137
Free cash flow
-1.05
-4.63
-90
-172
-89.8
-182
-263
Income taxes paid
0
0
0.48
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to May 31, 2026; growth uses fiscal years. Valuation uses the share price of $23.01 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-982.4%
Operating income / revenue.
EBITDA margin
-959.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-928.4%
Net income / revenue.
FCF margin
-828.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-798.8%
Cash from operations / revenue.
Return on equity (ROE)
-84.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-63.7%
Net income / average total assets.
Return on invested capital (ROIC)
-85.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
927.3%
Research and development expense / revenue.
Stock-based pay / revenue
107.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
29.4%
Capital expenditures / revenue.
D&A / revenue
23.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
54.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
29.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
36.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
2.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
21.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
13.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
2.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
18.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
11.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
29.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
21.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
40.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.34x
Current assets / current liabilities.
Quick ratio
0.94x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.94x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.33
Revenue / diluted weighted shares.
FCF per share
-$2.74
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.64
Cash from operations / diluted weighted shares.
Book value per share
$3.88
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
65.0x
Market cap / revenue.
P/B
5.93x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.93x
Market cap / tangible book value, when positive.
EV/Sales
63.1x
Enterprise value / revenue.
FCF yield
-12.8%
Free cash flow / market cap.
Earnings yield
-14.3%
Net income / market cap (the inverse of P/E).
What was Nurix Therapeutics, Inc.'s revenue in fiscal 2025?
Nurix Therapeutics, Inc. reported revenue of $84.0M for fiscal 2025, 54% higher than the year before.
Was Nurix Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $264.5M.
How much free cash flow did Nurix Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $249.5M minus capital expenditures of $14.0M left free cash flow of -$263.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.